Day: August 31, 2020

Why do Patients Discontinue Treatment?

The ARN-Trio registry recently hosted a webinar unlocking deep insights into the “Why” behind patients discontinuing prescription therapy. The recorded webinar is available here. ARN-Trio registry uniquely employs trained chart abstractors to review unstructured data for the 369,000 patients in the registry, identifying the actual reasons for discontinuations as recorded in the visit notes. Traditionally, …

Why do Patients Discontinue Treatment? Read More »

ARN-Trio Registry Highlights Major Shifts in Infliximab Biosimilar Use

Analysis of the American Rheumatology Network-Trio Health (ARN-Trio) registry finds a surge in new prescriptions for Merck’s Renflexis infliximab biosimilar. The ARN-Trio registry is the first rheumatology registry to combine pharmacy dispensing data with electronic medical records (EMR) to provide unparalleled real-world insights. ARN-Trio is the largest registry of biosimilar use in community rheumatology practice, …

ARN-Trio Registry Highlights Major Shifts in Infliximab Biosimilar Use Read More »

Scroll to Top

How Can We Help You?